Full Breakdown
Redefining Obesity: Clinical vs. Preclinical – A New Diagnostic Paradigm
6/3/2026, 12:59:02 AM
The Lancet Commission’s Core Proposal
In January 2025, a Lancet Diabetes & Endocrinology Commission of 56 experts rejected a single disease label for obesity. It introduced two categories: clinical obesity (excess fat causing organ dysfunction) and preclinical obesity (excess weight without dysfunction). Seventy-six medical societies endorsed the framework.
Historical Context and BMI Limits
Obesity has been measured by body-mass index (BMI). Early 20th-century studies linked high BMI to mortality; later work showed risk stems from comorbidities, not weight alone. Consequently, treatment often depends on qualifying diseases, leaving many high-BMI individuals without care.
Data Supporting the Distinction
- Nearly one billion people worldwide have obesity.
- U.S. NHANES (2021-2023, ?5,000 adults) shows ?25 % of normal-BMI participants meet clinical-obesity criteria; >50 % of overweight participants do.
- Using two or three abnormal anthropometric measures raises excess-adiposity detection to 78 % (vs. 41 % with BMI + one measure).
Official Statements
The commission said a single disease label is incompatible with obesity’s varied manifestations. It defined clinical obesity as excess fat that directly impairs daily activities or causes organ dysfunction, and preclinical obesity as excess weight with preserved organ function.
Criticism & Opposition
Critics argue the diagnostic threshold is impractical because proving causality between excess fat and organ dysfunction is difficult. They warn the preclinical category could restrict treatment access and contend that common comorbidities such as type 2 diabetes should be part of the clinical definition.
Conflicting Reports & Gaps
Research finds no universal genetic marker for obesity; “there are no known genetic abnormalities that are shared across all people with obesity.” Disagreement persists on whether obesity should be a disease at the population level versus the individual level, leaving diagnostic standards unsettled.
Why It Matters
Distinguishing clinical from preclinical obesity aligns treatment with organ impairment, reduces stigma, and informs insurance and public-health policy. It also offers a clearer research target by anchoring disease definitions in observable dysfunction rather than BMI alone.
Verbatim Quotes
- “Critics argue that it sets an impractical diagnostic threshold, because of the challenges of demonstrating that excess fat directly causes a person’s organ dysfunction.” — Unnamed Critics, Scientific Societies
- “They worry that the existence of the preclinical category might lead to restricted access to treatment for some people.” — Unnamed Critics, Scientific Societies
- “BMI can’t be used to predict an individual’s clinical status, prognosis or response to treatment, or to understand the biological underpinnings of their weight.” — Article Author, Lancet Commission
- “The concept of “clinical obesity,” introduced by the Lancet Diabetes & Endocrinology Commission, aims to transcend the limitations of BMI alone by including assessments of body fat distribution and evidence of compromised organ or physical function.” — Researchers, University of Southern California
What’s Next
Ongoing research aims to develop standardized, cost-effective protocols combining anthropometric, functional and biochemical markers. Adoption of clinical-obesity criteria into national guidelines could reshape screening, prevention and reimbursement worldwide.
